FDA Warning Letter to Estar Technologies Ltd (2026-04-22) — Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device
Letter issued · posted to fda.gov .
Subject as published: Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device
TL;DR
Key takeaway: FDA issued a Warning Letter to Estar Technologies Ltd on 2026-04-22 citing: Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/estar-technologies-ltd-716831-04222026
Argus analysis
Estar Technologies Ltd (MARCS-CMS 716831) received an FDA Warning Letter dated April 22, 2026 from the Center for Biologics Evaluation and Research. The letter cites: Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on May 12, 2026.
Device PMA/IDE letters cite 21 CFR Part 812 (investigational device exemptions) or Part 814 (premarket approval), alongside adulteration provisions in 21 USC 351. Common findings involve marketing or distributing a significant-risk device without an approved PMA or IDE, or failing to maintain the records an approved application requires.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same general compliance category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Estar Technologies Ltd MARCS-CMS 716831 — April 22, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via UPS and EMAIL Reference #: CBER 26-716831 Product: Biologics Medical Devices Recipient: Recipient Name Aaron Esteron Recipient Title Chief Executive Officer and Founder Estar Technologies Ltd 15, Ha-Merkava Holon 5885111 Israel Aaron@estar-medical.com Issuing Office: Center for Biologics Evaluation and Research United States WARNING LETTER April 22, 2026 CBER 26-716831 Dear Mr. Esteron: The United States Food and Drug Administration (FDA) has learned that your firm is offering for sale the Tropocells® PRP kit, Tropocells® PRF kit, Tropocells® TRS kit, Tropocells® PRFM kit, TropoVisc™ kit, Tropokine™ kit, and Cellenis® PRP kit (hereafter, “your devices”) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), your devices are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or any function of the body. Based on information and records reviewed by FDA, including your websites at https://www.tropocells.com and https://estar-medical.com/ (last visited April 2026), your devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your introduction or delivery for introduction of your devices into interstate commerce, or the causing thereof is a prohibited act under section 301(a) of the Act, 21 U.S.C. § 331(a). Your devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce your devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a). Of note, the TropoCells® PRP kit was cleared under premarket notification (510(k)) submission number BK110035 with the following indication, “safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care. The PRP is mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics.” However, you include statements such as the following on your website, https://www.tropocells.com, regarding the uses of the Tropocells® PRP kit: “Tropocells® PRP is the ideal autologous technology for the healing of: musculoskeletal injuries, joint and osteoarthritis treatment, sports injuries, wound healing, ophthalmology, dentistry and oral surgery, and post-surg…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Warning Letter warning letter?
- FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Estar Technologies Ltd had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Estar Technologies Ltd as of 2026-05-12. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to Estar Technologies Ltd (2026-04-22) — Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-estar-technologies-ltd-2026-04-22-warning-letter
"FDA Warning Letter to Estar Technologies Ltd (2026-04-22) — Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-estar-technologies-ltd-2026-04-22-warning-letter.
Argus HQ Research. "FDA Warning Letter to Estar Technologies Ltd (2026-04-22) — Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-estar-technologies-ltd-2026-04-22-warning-letter.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_estar_technologies_ltd_2026_04_22_warning_letter_2026,
title = {FDA Warning Letter to Estar Technologies Ltd (2026-04-22) — Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-estar-technologies-ltd-2026-04-22-warning-letter},
note = {Accessed: July 13, 2026}
}